

Michaela Lackner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1951614/publications.pdf>

Version: 2024-02-01

101
papers

5,557
citations

117625

34
h-index

85541

71
g-index

106
all docs

106
docs citations

106
times ranked

5048
citing authors

#	ARTICLE	IF	CITATIONS
1	An overview of using fungal DNA for the diagnosis of invasive mycoses. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 169-184.	3.1	18
2	N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro. <i>Emerging Microbes and Infections</i> , 2022, , 1-49.	6.5	7
3	Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. <i>Medical Mycology</i> , 2021, 59, 126-138.	0.7	27
4	Impact of biofilm formation and azoles' susceptibility in <i>Scenedosporium/Lomentospora</i> species using an in vitro model that mimics the cystic fibrosis patients' airway environment. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 303-309.	0.7	9
5	<i>N</i> -chlorotaurine, a potent weapon against multiresistant bacteria. <i>Journal of Applied Microbiology</i> , 2021, 131, 1742-1748.	3.1	8
6	The Environmental Spread of <i>Aspergillus terreus</i> in Tyrol, Austria. <i>Microorganisms</i> , 2021, 9, 539.	3.6	7
7	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The. 2021, 21, e246-e257.	9.1	167
8	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and <i>Aspergillus</i> spp. to Caspofungin: Further Assessment of Modal Variability. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0109321.	3.2	12
9	EQUAL Score Scenedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 253-258.	3.0	13
10	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 4.	3.5	5
11	Sterol 14 α -Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 1.	3.5	67
12	Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. <i>Blood Cancer Journal</i> , 2020, 10, 75.	6.2	2
13	Comparative immunopathogenesis in a murine model of inhalative infection with the mucormycetes <i>Lichtheimia corymbifera</i> and <i>Rhizopus arrhizus</i> . <i>PLoS ONE</i> , 2020, 15, e0234063.	2.5	6
14	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope's Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	3.3	20
15	Microbicidal activity of N-chlorotaurine can be enhanced in the presence of lung epithelial cells. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 1011-1017.	0.7	3
16	Antifungal susceptibility testing in <i>Candida</i> , <i>Aspergillus</i> and <i>Cryptococcus</i> infections: are the MICs useful for clinicians?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1024-1033.	6.0	23
17	Polymorphisms within the <i>ARNT2</i> and <i>CX3CR1</i> Genes Are Associated with the Risk of Developing Invasive Aspergillosis. <i>Infection and Immunity</i> , 2020, 88, .	2.2	8
18	Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing <i>Saccharomycotina</i> yeasts. <i>Medical Mycology</i> , 2020, 58, 987-995.	0.7	14

#	ARTICLE	IF	CITATIONS
19	<i>Galleria mellonella</i> as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment. <i>Medical Mycology</i> , 2019, 57, 351-362.	0.7	54
20	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 532-533.	3.0	3
21	Cryptic species of <i>Aspergillus</i> section <i>Terrei</i> display essential physiological features to cause infection and are similar in their virulence potential in <i>Galleria mellonella</i> . <i>Virulence</i> , 2019, 10, 542-554.	4.4	14
22	Evaluation of a Novel Mitochondrial Pan-Mucorales Marker for the Detection, Identification, Quantification, and Growth Stage Determination of Mucormycetes. <i>Journal of Fungi (Basel)</i> , 2019, 5, 1650-1617.	1.6	1
23	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , 2019, 19, e405-e421.	9.1	970
24	A European ECMM-ESCMID survey on goals and practices for mycobiota characterisation using next-generation sequencing. <i>Mycoses</i> , 2019, 62, 1096-1099.	4.0	8
25	The Emergence of Rare Clinical <i>Aspergillus</i> Species in Qatar: Molecular Characterization and Antifungal Susceptibility Profiles. <i>Frontiers in Microbiology</i> , 2019, 10, 1677.	3.5	22
26	Minimal Inhibitory Concentration (MIC)-Phenomena in <i>Candida albicans</i> and Their Impact on the Diagnosis of Antifungal Resistance. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 83.	3.5	10
27	Enhanced acquisition of antibiotic-resistant intestinal <i>E. coli</i> during the first year of life assessed in a prospective cohort study. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 79.	4.1	12
28	Antifungal susceptibility profiles of rare ascomycetous yeasts. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2649-2656.	3.0	22
29	Recent trends in molecular diagnostics of yeast infections: from PCR to NGS. <i>FEMS Microbiology Reviews</i> , 2019, 43, 517-547.	8.6	77
30	The changing spectrum of <i>Saccharomycotina</i> yeasts causing candidemia: phylogeny mirrors antifungal susceptibility patterns for azole drugs and amphotericin B. <i>FEMS Yeast Research</i> , 2019, 19, .	2.3	30
31	<i>Candida</i> in the Respiratory Tract Potentially Triggers Galactomannan Positivity in Nonhematological Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
32	Low Level of Antifungal Resistance in Iranian Isolates of <i>Candida glabrata</i> Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of PDR1. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	39
33	High percentage of microbial colonization of osteosynthesis material in clinically unremarkable patients. <i>MicrobiologyOpen</i> , 2019, 8, e00658.	3.0	16
34	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and <i>FungiScope</i> . <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	6.1	106
35	Analysis of antifungal resistance genes in <i>Candida albicans</i> and <i>Candida glabrata</i> using next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0210397.	2.5	53
36	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	59

#	ARTICLE	IF	CITATIONS
37	Novel multiplex real-time quantitative PCR detecting system approach for direct detection of <i>Candida auris</i> and its relatives in spiked serum samples. <i>Future Microbiology</i> , 2019, 14, 33-45.	2.0	38
38	YEAST PANEL multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 112-119.	1.8	42
39	Direct detection of <i>Exophiala</i> and <i>Scedosporium</i> species in sputa of patients with cystic fibrosis. <i>Medical Mycology</i> , 2018, 56, 695-702.	0.7	16
40	<i>Scedosporium</i> and <i>Lomentospora</i> : an updated overview of underrated opportunists. <i>Medical Mycology</i> , 2018, 56, S102-S125.	0.7	186
41	N-Chlorotaurine, a Promising Future Candidate for Topical Therapy of Fungal Infections. <i>Mycopathologia</i> , 2018, 183, 161-170.	3.1	24
42	403. Prognostic Factors in 260 Adults With Invasive <i>Scedosporiosis</i> From Literature and <i>FungiScope</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S155-S155.	0.9	0
43	Azole-resistant and -susceptible <i>Aspergillus fumigatus</i> isolates show comparable fitness and azole treatment outcome in immunocompetent mice. <i>Medical Mycology</i> , 2018, 56, 703-710.	0.7	8
44	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
45	A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria. <i>Infection</i> , 2018, 46, 701-704.	4.7	11
46	Proof of Concept for MBT ASTRA, a Rapid Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS)-Based Method To Detect Caspofungin Resistance in <i>Candida albicans</i> and <i>Candida glabrata</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	52
47	Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within <i>Aspergillus</i> section <i>Terrei</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3068-3073.	3.0	32
48	Voriconazole MICs are predictive for the outcome of experimental disseminated <i>scedosporiosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw532.	3.0	14
49	Pan-azole-resistant <i>Candida tropicalis</i> carrying homozygous <i>erg11</i> mutations at position K143R: a new emerging superbug?. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw558.	3.0	35
50	Bactericidal and Fungicidal Activity of N-Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
51	A prospective international <i>Aspergillus terreus</i> survey: an EFISC, ISHAM and ECMM joint study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 776.e1-776.e5.	6.0	42
52	Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience. <i>Infection</i> , 2017, 45, 867-875.	4.7	19
53	Impact of Morphological Sectors on Antifungal Susceptibility Testing and Virulence Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	7
54	Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved amino acid substitution of the lanosterol 14 α -demethylase. <i>Scientific Reports</i> , 2017, 7, 15898.	3.3	59

#	ARTICLE	IF	CITATIONS
55	Retrospective case study on the suitability of mid-infrared microscopic imaging for the diagnosis of mucormycosis in human tissue sections. <i>Analytical Methods</i> , 2017, 9, 4135-4142.	2.7	4
56	Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in <i>Candida</i> spp. and <i>Aspergillus</i> spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	47
57	Commercial Molecular Tests for Fungal Diagnosis from a Practical Point of View. <i>Methods in Molecular Biology</i> , 2017, 1508, 85-105.	0.9	10
58	Common Genetic Polymorphisms within NF κ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	3.5	13
59	Geographically predominant genotypes of <i>Aspergillus terreus</i> species complex in Austria: a microsatellite typing study. <i>Clinical Microbiology and Infection</i> , 2016, 22, 270-276.	6.0	23
60	Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOMics Consortium. <i>Infection and Immunity</i> , 2016, 84, 643-657.	2.2	35
61	Prospective multicentre PCR-based <i>Aspergillus</i> DNA screening in high-risk patients with and without primary antifungal mould prophylaxis. <i>Clinical Microbiology and Infection</i> , 2016, 22, 80-86.	6.0	60
62	The "species complex" issue in clinically relevant fungi: A case study in <i>Scedosporium apiospermum</i> . <i>Fungal Biology</i> , 2016, 120, 137-146.	2.5	54
63	DNA barcoding of fungi causing infections in humans and animals. <i>Fungal Biology</i> , 2016, 120, 125-136.	2.5	67
64	Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. <i>Journal of Medical Microbiology</i> , 2016, 65, 1414-1421.	1.8	62
65	Diagnostic accuracy of the <i>Aspergillus</i> -specific bronchoalveolar lavage lateral flow assay in haematological malignancy patients. <i>Mycoses</i> , 2015, 58, 461-469.	4.0	51
66	<i>N</i> -Chlorotaurine Exhibits Fungicidal Activity against Therapy-Refractory <i>Scedosporium</i> Species and <i>Lomentospora prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6454-6462.	3.2	16
67	Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. <i>European Journal of Haematology</i> , 2015, 94, 258-264.	2.2	35
68	Susceptibility Profiles of Amphotericin B and Posaconazole against Clinically Relevant Mucorales Species under Hypoxic Conditions. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1344-1346.	3.2	15
69	Multidrug- and Cross-Resistant <i>Candida</i> : the Looming Threat. <i>Current Fungal Infection Reports</i> , 2015, 9, 23-36.	2.6	3
70	Evaluation of a Modified EUCAST Fragmented-Mycelium Inoculum Method for <i>In Vitro</i> Susceptibility Testing of Dermatophytes and the Activity of Novel Antifungal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3675-3682.	3.2	12
71	Effect of Reduced Oxygen on the Antifungal Susceptibility of Clinically Relevant <i>Aspergilli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1806-1810.	3.2	12
72	Etest Cannot Be Recommended for <i>In Vitro</i> Susceptibility Testing of Mucorales. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3663-3665.	3.2	29

#	ARTICLE	IF	CITATIONS
73	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. <i>Critical Care</i> , 2015, 19, 178.	5.8	65
74	Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. <i>British Journal of Cancer</i> , 2015, 113, 970-978.	6.4	21
75	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1056-1062.	3.9	65
76	1462Bronchoalveolar Lavage Lateral-Flow Device Test for Diagnosing Invasive Pulmonary Aspergillosis in ICU patients: a multicenter study. <i>Open Forum Infectious Diseases</i> , 2014, 1, S385-S386.	0.9	1
77	Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis in Solid Organ Transplant Patients: A Semi-Prospective Multicenter Study.. <i>Transplantation</i> , 2014, 98, 775.	1.0	0
78	Laboratory diagnosis of mucormycosis: current status and future perspectives. <i>Future Microbiology</i> , 2014, 9, 683-695.	2.0	105
79	Phylogenetic Relationships Matter: Antifungal Susceptibility among Clinically Relevant Yeasts. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1575-1585.	3.2	26
80	Positions and Numbers of <i>FKS</i> Mutations in <i>Candida albicans</i> Selectively Influence <i>In Vitro</i> and <i>In Vivo</i> Susceptibilities to Echinocandin Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3626-3635.	3.2	59
81	Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis in Solid Organ Transplant Patients. <i>Transplantation</i> , 2014, 98, 898-902.	1.0	54
82	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <i>Clinical Microbiology and Infection</i> , 2014, 20, 27-46.	6.0	383
83	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014, 20, 47-75.	6.0	262
84	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014, 20, 5-26.	6.0	547
85	Proposed nomenclature for <i>Pseudallescheria</i> , <i>Scedosporium</i> and related genera. <i>Fungal Diversity</i> , 2014, 67, 1-10.	12.3	152
86	Susceptibility and Diversity in the Therapy-Refractory Genus <i>Scedosporium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5877-5885.	3.2	61
87	Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to <i>Scedosporium apiospermum</i> and <i>Scedosporium boydii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3027-3032.	3.0	16
88	<i>In Vitro</i> Antifungal Susceptibility of <i>Candida glabrata</i> to Caspofungin and the Presence of <i>FKS</i> Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3646-3649.	3.2	10
89	Feasibility of mitochondrial single nucleotide polymorphisms to detect and identify <i>Aspergillus fumigatus</i> in clinical samples. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 53-58.	1.8	8
90	Taxonomy of medically important fungi in the molecular era. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 385-386.	9.1	31

#	ARTICLE	IF	CITATIONS
91	Pathogenesis of <i>Scedosporium</i> . <i>Current Fungal Infection Reports</i> , 2013, 7, 326-333.	2.6	19
92	<i>In vitro</i> activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. <i>Mycoses</i> , 2013, 56, 297-303.	4.0	29
93	SNaPAfu: A Novel Single Nucleotide Polymorphism Multiplex Assay for <i>Aspergillus fumigatus</i> Direct Detection, Identification and Genotyping in Clinical Specimens. <i>PLoS ONE</i> , 2013, 8, e75968.	2.5	13
94	Up-date on Diagnostic Strategies of Invasive Aspergillosis. <i>Current Pharmaceutical Design</i> , 2013, 19, 3595-3614.	1.9	50
95	Species-Specific Antifungal Susceptibility Patterns of <i>Scedosporium</i> and <i>Pseudallescheria</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2635-2642.	3.2	244
96	Rapid Identification of <i>Pseudallescheria</i> and <i>Scedosporium</i> Strains by Using Rolling Circle Amplification. <i>Applied and Environmental Microbiology</i> , 2012, 78, 126-133.	3.1	44
97	Young ISHAM “Uniting Young Scientists from all over the World. <i>Current Fungal Infection Reports</i> , 2012, 6, 346-348.	2.6	0
98	PHP124 Personalized Decision Making in Cancer Medicine? Systematic Overview of HTA Procedures and Specific Approaches in Ten Countries Across Four Continents. <i>Value in Health</i> , 2011, 14, A355-A356.	0.3	0
99	Severe prosthetic joint infection in an immunocompetent male patient due to a therapy refractory <i>Pseudallescheria apiosperma</i> . <i>Mycoses</i> , 2011, 54, 22-27.	4.0	26
100	Identification of <i>Pseudallescheria</i> and <i>Scedosporium</i> Species by Three Molecular Methods. <i>Journal of Clinical Microbiology</i> , 2011, 49, 960-967.	3.9	51
101	<i>Parascedosporium</i> and its relatives: phylogeny and ecological trends. <i>IMA Fungus</i> , 2011, 2, 39-48.	3.8	28